Stellantis idles plants in Mexico and Canada due to tariffs
Stellantis is pausing production at the automaker’s Windsor Assembly Plant in Ontario, Canada, and its Toluca Assembly Plant in Mexico.
Related Articles
ISAF approves equecabtagene autoleucel for relapsed or refractory multiple myeloma – SOHO Insider
FUCASO, equecabtagene autoleucel, approved in Macao for MM in 2025, based on FUMANBA-1 phase 1/2 trial, per IASO Bio
UK MHRA Approves GSK’s BLENREP® in Combination with BVd and BPd for the Treatment of Adult RRMM Patients
UK Medicine and Healthcare products Regulatory Agency (MHRA) authorizes use of Blenrep (belantamab mafodotin) for the treatment of adults with multiple myeloma in combination with bortezomib plus…
Simple local composite flap for a large superior helical rim defect
Large helical rim defects disrupt the unique curvature, contour, and symmetry of the ear. Techniques commonly used for repair include two-stage retroauricular pedicled (interpolation) flaps,…
Lilly’s oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial | Eli Lilly and Company
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Free Event: 2025 Food Revolution Summit
Find out what the world’s top doctors eat for disease prevention, energy, mental health, and longevity — April 23rd – April 30th, 2025.
Investigational BTK Inhibitor Rilzabrutinib Receives FDA Orphan Drug Designation For 2 Rare Diseases | Docwire News
The FDA has granted orphan drug designation to rilzabrutinib for the treatment of warm autoimmune hemolytic anemia and and IgG4-related disease.
Plant-Based Protein Linked to Longer Lifespan
A study reveals that populations with access to plant-based protein sources have longer life expectancies. The research shows that while animal protein is beneficial for…
Plant-Based Diets: Benefits for Your Health and the Environment | SBM – Society of Behavioral Medicine
What we eat doesn’t just affect our bodies. It also affects the health of our planet. Plant-based diets are gaining attention for their potential to…
SOHO Insider – AFM13 Shows Promise in CD30 Lymphoma Trial
AFM13 with NK cells yields 92.9% response in CD30 lymphoma refractory to brentuximab, per phase 1 trial in Nature Medicine.
Recent Breakthroughs in Hodgkin Lymphoma and What to Expect in 2025 | Blood Cancers Today
Andrew M. Evens, DO, MBA, MSc, shared practice-changing studies in Hodgkin lymphoma and what to expect in the clinical trial space in 2025.
